{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:05:59Z","timestamp":1792785959699,"version":"4.5.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"MicuRx Pharmaceuticals Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Contezolid is a novel oxazolidinone antibacterial agent for managing infections caused by aerobic and anaerobic Gram-positive bacteria including methicillin-resistant strains. A Phase III, multicentre, randomized, double-blind, active-controlled trial evaluated the efficacy and safety of contezolid versus linezolid in adults with complicated skin and soft tissue infections (cSSTIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients with cSSTI were randomized in a ratio of 1:1 to receive contezolid 800\u2005mg or linezolid 600\u2005mg q12h for 7\u201314\u2005days. Clinical cure rate and safety were assessed at the test of cure (TOC) visit in the full analysis set (FAS) and clinical evaluable (CE) population. Non-inferiority was defined as a lower limit of the 95% CI around the treatment difference of clinical cure rates greater than \u221210%. Chinadrugtrials.org.cn registration identifier: CTR20150855.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Clinical cure rates at TOC indicated non-inferiority of contezolid 800\u2005mg to linezolid 600\u2005mg q12h for patients in the FAS with clinical evaluation, FAS, and CE populations: 92.8% (271\/292) versus 93.4% (284\/304) (difference \u22120.6%, 95% CI: \u22124.7% to 3.5%), 81.4% (271\/333) versus 84.5% (284\/336) (difference \u22123.1%, 95% CI: \u22128.8% to 2.6%) and 90.5% (267\/295) versus 90.1% (282\/313) (difference 0.4%, 95% CI: \u22124.3% to 5.1%). Contezolid and linezolid showed similar efficacy for the cSSTIs caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus. Contezolid demonstrated significant lower incidence of leucopenia (0.3% versus 3.4%) and thrombocytopenia (0% versus 2.3%) than linezolid. The frequency of treatment-emergent adverse events was comparable between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Contezolid 800\u2005mg q12h is as effective as linezolid for treatment of cSSTIs in adults, but safer than linezolid in terms of haematological abnormalities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkac073","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T23:12:36Z","timestamp":1645744356000},"page":"1762-1769","source":"Crossref","is-referenced-by-count":55,"title":["A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections"],"prefix":"10.1093","volume":"77","author":[{"given":"Xu","family":"Zhao","sequence":"first","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai, China"},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihui","family":"Huang","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai, China"},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Shanghai MicuRx Pharmaceutical Co., Ltd. , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyu","family":"Yuan","sequence":"additional","affiliation":[{"name":"Shanghai MicuRx Pharmaceutical Co., Ltd. , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai, China"},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"issue":"Suppl 3","key":"2022053122482823700_dkac073-B1","first-page":"iii35","article-title":"Complicated skin and soft tissue infection","volume":"65","author":"Dryden","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"2022053122482823700_dkac073-B2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0924-8579(15)30002-9","article-title":"Managing skin and soft-tissue infection and nosocomial pneumonia caused by MRSA: a 2014 follow-up survey","volume":"45","author":"Dryden","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2022053122482823700_dkac073-B3","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJMcp070747","article-title":"Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus","volume":"357","author":"Daum","year":"2007","journal-title":"N Engl J Med"},{"key":"2022053122482823700_dkac073-B4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/QCO.0000000000000239","article-title":"Epidemiology and microbiology of skin and soft tissue infections","volume":"29","author":"Esposito","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"2022053122482823700_dkac073-B5","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2022053122482823700_dkac073-B6","first-page":"CD008056","article-title":"Linezolid versus vancomycin for skin and soft tissue infections","author":"Yue","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"2022053122482823700_dkac073-B7","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1093\/cid\/cit614","article-title":"Methicillin-resistant Staphylococcus aureus therapy: past, present, and future","volume":"58","author":"Rodvold","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2022053122482823700_dkac073-B8","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/QCO.0000000000000432","article-title":"Is there still a role for vancomycin in skin and soft-tissue infections?","volume":"31","author":"Savoldi","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"2022053122482823700_dkac073-B9","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1128\/AAC.03147-14","article-title":"Optimizing the clinical use of vancomycin","volume":"60","author":"\u00c1lvarez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022053122482823700_dkac073-B10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40262-020-00964-1","article-title":"Supra-therapeutic linezolid trough concentrations in elderly patients: A call for action?","volume":"60","author":"Cattaneo","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2022053122482823700_dkac073-B11","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/bcp.13262","article-title":"Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients","volume":"83","author":"Tsuji","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2022053122482823700_dkac073-B12","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jiac.2016.05.003","article-title":"A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia","volume":"22","author":"Hanai","year":"2016","journal-title":"J Infect Chemother"},{"key":"2022053122482823700_dkac073-B13","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1021\/jm401931e","article-title":"New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile","volume":"57","author":"Gordeev","year":"2014","journal-title":"J Med Chem"},{"key":"2022053122482823700_dkac073-B14","doi-asserted-by":"crossref","first-page":"e01195-20","DOI":"10.1128\/AAC.01195-20","article-title":"In vitro activity and potency of the novel oxazolidinone contezolid (MRX-I) tested against gram-Positive clinical isolates from the United States and Europe","volume":"64","author":"Carvalhaes","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2022053122482823700_dkac073-B15","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1128\/AAC.01526-13","article-title":"In vivo antibacterial activity of MRX-I, a new oxazolidinone","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022053122482823700_dkac073-B16","article-title":"Acute and Repeat Dose Toxicity of MRX-I in Rat","volume-title":"Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, USA, 2012","author":"Qiu"},{"key":"2022053122482823700_dkac073-B17","doi-asserted-by":"crossref","first-page":"e02181-16","DOI":"10.1128\/AAC.02181-16","article-title":"Single- and multiple-dose study to determine the safety, tolerability, pharmacokinetics, and food effect of oral MRX-I versus linezolid in healthy adult subjects","volume":"61","author":"Eckburg","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2022053122482823700_dkac073-B18","first-page":"121","article-title":"In vitro activities of contezolid against clinical isolates from China","volume":"21","author":"Zhu","year":"2021","journal-title":"Chin J Infect Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/6\/1762\/43893415\/dkac073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/6\/1762\/43893415\/dkac073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T18:50:24Z","timestamp":1654023024000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/6\/1762\/6546016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3,10]]},"published-print":{"date-parts":[[2022,5,29]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac073","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,3,10]]}}}